Steris (NYSE: STE) reported Q4 EPS of $1.53, $0.10 better than the analyst estimate of $1.43. Revenue for the quarter came in at $768.2 million versus the consensus estimate of $738.5 million.

GUIDANCE:

Steris sees FY2020 EPS of $5.28-$5.43, versus the consensus of $5.29.

STERIS expects constant currency organic revenue growth to be in the range of 5-6% for fiscal 2020. Reflecting March 29, 2019 forward rates, currency movements are anticipated to be neutral for fiscal 2020. Adjusted earnings per diluted share are anticipated to be in the range of $5.28 - $5.43, which assumes an adjusted effective tax rate in the range of 19-20%.

Free cash flow for fiscal 2020 is expected to be approximately $300 million, and capital spending is anticipated to be approximately $280 million. Growth in cash from operations in fiscal 2020 will be more than offset by significantly higher capital spending, limiting free cash flow for the year. In particular, growth capital of more than $110 million will be invested to expand global capacity in the Applied Sterilization Technologies segment. In addition, investments will continue to be made to

For earnings history and earnings-related data on Steris (STE) click here.